Form 605

Corporations Act 2001 Section 671B

Notice of ceasing to be a substantial holder

The Company Secretary

To Company Name/Scheme

Vision Eye Institute Limited ("VEI") Level 5, 390 St Kilda Road MELBOURNE, VIC 3004 Facsimile: (03) 8844 4099

ACN/ARSN 098 890 816

1. Details of substantial holder

Name
Primary Health Care Limited (ACN 064 530 516) ("PRY") and each body corporate it controls listed in

Annexure A, which includes Idameneo (No. 123) Pty Ltd ("IPL") (ACN 002 968 185)

ACN/ARSN (if applicable)

The holder ceased to be a substantial holder on 07/08/2015

The previous notice was given to the company on 10/07/2014

The previous notice was dated 10/07/2014

As announced to the market on 31 July 2015, PRY (through its wholly owned subsidiary IPL) entered into an agreement to sell 35,984,135 ordinary voting shares in VEI to Jangho Group Co. Ltd (or its nominee) ("**JGC**"). A copy of the Share Sale Agreement dated 30 July 2015 is attached as Annexure B of 4 pages.

This sale, in conjunction with some additional sales of ordinary voting shares by IPL, has resulted in PRY and its body corporates listed in Annexure A ceasing to be substantial holders of VEI from 7 August 2015.

2. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

| Date of change | Person whose relevant interest changed | Nature of change | Consideration given in relation to change | Class and number of securities affected | Person's votes affected |
|----------------|--|--------------------|---|---|-------------------------|
| 11-Jul-14 | IPL | On-market purchase | \$0.7698 | 193,050 | 193,050 |
| 14-Jul-14 | IPL | On-market purchase | \$0.7442 | 127,819 | 127,819 |
| 15-Jul-14 | IPL | On-market purchase | \$0.7500 | 37,387 | 37,387 |
| 16-Jul-14 | IPL | On-market purchase | \$0.7500 | 11,713 | 11,713 |
| 18-Jul-14 | IPL | On-market purchase | \$0.7495 | 437,134 | 437,134 |
| 21-Jul-14 | IPL | On-market purchase | \$0.7345 | 106,306 | 106,306 |
| 22-Jul-14 | IPL | On-market purchase | \$0.7364 | 56,067 | 56,067 |
| 23-Jul-14 | IPL | On-market purchase | \$0.7300 | 13,934 | 13,934 |
| 25-Jul-14 | IPL | On-market purchase | \$0.7494 | 54,292 | 54,292 |
| 01-Aug-14 | IPL | On-market sale | \$0.7915 | (119,057) | (119,057) |
| 05-Aug-14 | IPL | On-market sale | \$0.7922 | (64,946) | (64,946) |

| 07-Aug-14 | IPL | On-market sale | \$0.7900 | (17,110) | (17,110) |
|-----------|-----|--|----------|--------------|--------------|
| 07-Aug-14 | IPL | On-market sale | \$0.7710 | (59,251) | (59,251) |
| 08-Aug-14 | IPL | On-market sale | \$0.7700 | (9,000) | (9,000) |
| 11-Aug-14 | IPL | On-market sale | \$0.6994 | (251,471) | (251,471) |
| 12-Aug-14 | IPL | On-market sale | \$0.6784 | (602,200) | (602,200) |
| 13-Aug-14 | IPL | On-market sale | \$0.7050 | (100,000) | (100,000) |
| 01-Sep-14 | IPL | On-market sale | \$0.7150 | (50,000) | (50,000) |
| 07-Oct-14 | IPL | On-market sale | \$0.6307 | (300,000) | (300,000) |
| 08-Oct-14 | IPL | On-market sale | \$0.6325 | (100,000) | (100,000) |
| 09-Oct-14 | IPL | On-market sale | \$0.6214 | (525,000) | (525,000) |
| 09-Oct-14 | IPL | On-market sale | \$0.6225 | (109,637) | (109,637) |
| 17-Oct-14 | IPL | On-market purchase | \$0.6300 | 24,000 | 24,000 |
| 20-Oct-14 | IPL | On-market purchase | \$0.6550 | 63,085 | 63,085 |
| 21-Oct-14 | IPL | On-market purchase | \$0.6550 | 33,937 | 33,937 |
| 22-Oct-14 | IPL | On-market purchase under share placement | \$0.6000 | 3,396,237 | 3,396,237 |
| 23-Oct-14 | IPL | On-market purchase | \$0.7000 | 2,500,000 | 2,500,000 |
| 29-Oct-14 | IPL | On-market purchase | \$0.7320 | 231,440 | 231,440 |
| 30-Oct-14 | IPL | On-market purchase | \$0.7292 | 500,000 | 500,000 |
| 06-Aug-15 | IPL | On-market sale | \$0.8546 | (524,839) | (524,839) |
| 06-Aug-15 | IPL | On-market sale | \$0.8630 | (549,222) | (549,222) |
| 07-Aug-15 | IPL | On-market sale | \$0.8752 | (1,528,218) | (1,528,218) |
| 07-Aug-15 | IPL | Off-market sale pursuant to a Share Sale Agreement between IPL and JGC dated 30 July 2015 (see Annexure B) | \$0.9400 | (35,984,135) | (35,984,135) |
| 10-Aug-15 | IPL | On-market sale | \$0.9253 | (585,756) | (585,756) |

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

| Name and ACN/ARSN (if applicable) | Nature of association |
|-----------------------------------|-----------------------|
| Not applicable | |
| | |

4. Addresses

The addresses of persons named in this form are as follows:

| Name | Address |
|---|---|
| Primary Health Care Limited (ACN 064 530 516) ("PRY") and each body corporate it controls listed in Annexure A, which includes Idameneo (No. 123) Ptv Ltd ("IPL") (ACN 002 968 185) | Level 1, 30-38 Short Street Leichhardt NSW 2040 |

| Si | an | at | ure | |
|----|----|----|-----|--|
| | J | | | |

sign here CHARLES TILLEY capacity COMPANY SECRETARY

date 10/08/2015

Vision Eye Institute Limited (ACN 098 890 816)

Annexure A

This is Annexure A of 2 pages referred to in Form 605 Notice of ceasing to be a substantial shareholder.

Signature

| print name | CHARLES TILLEY | capacity COMPANY SECRETARY |
|------------|----------------|----------------------------|
| sign here | Um Tilly | date 10/08/2015 |

Bodies Corporate controlled by Primary Health Care Limited

| Company Name | ACN / Company Number | Country |
|---|----------------------|-----------|
| ACN 008 103 599 Pty Ltd | 008 103 599 | Australia |
| ACN 063 535 884 Pty Ltd | 063 535 884 | Australia |
| ACN 063 535 955 Pty Ltd | 063 535 955 | Australia |
| Aksertel Pty Ltd | 092 452 269 | Australia |
| AME Medical Services Pty Ltd | 009 136 118 | Australia |
| Amokka Java Pty Limited | 093 516 986 | Australia |
| Austrials Pty Ltd | 138 935 403 | Australia |
| Brystow Pty Ltd | 003 377 633 | Australia |
| Campbelltown MRI Pty Ltd | 139 528 662 | Australia |
| Digital Diagnostic Imaging Pty Ltd | 092 222 181 | Australia |
| Former AP Pty Ltd | 096 615 913 | Australia |
| Former SDS Pty Ltd | 003 417 605 | Australia |
| Health Communication Network Limited | 068 458 515 | Australia |
| Healthcare Imaging Services (South Australia) Pty Ltd | 136 806 776 | Australia |
| Healthcare Imaging Services (Victoria) Pty Ltd | 085 350 189 | Australia |
| Healthcare Imaging Services (Western Australia) Pty Ltd | 136 806 865 | Australia |
| Healthcare Imaging Services Pty Ltd | 080 595 937 | Australia |
| Idameneo (No. 123) Pty Ltd | 002 968 185 | Australia |
| Idameneo (No. 124) Pty Ltd | 123 864 479 | Australia |
| Idameneo (No. 125) Pty Ltd | 162 662 919 | Australia |
| Idameneo (No. 789) Limited | 004 073 410 | Australia |
| Idameneo UK Ltd | 639379 | UK |
| Integrated Health Care Pty Ltd | 009 145 493 | Australia |
| Jandale Pty Ltd | 009 355 284 | Australia |
| John R Elder Pty Ltd | 002 940 874 | Australia |
| Kelldale Pty Ltd | 002 861 770 | Australia |
| Larches Pty Ltd | 061 980 943 | Australia |
| Mayne Nickless Incorporated | 91-1148148 | USA |
| MGSF Pty Ltd | 065 190 132 | Australia |

| Moaven & Partners Pathology Pty Ltd | 108 869 647 | Australia |
|--|-----------------------|-------------|
| Norcoray Pty Ltd | 074 275 040 | Australia |
| Northcoast Nuclear Medicine (Qld) Pty Ltd | 107 700 569 | Australia |
| Onosas Pty Ltd | 092 452 214 | Australia |
| Orana Services Pty Ltd | 088 631 949 | Australia |
| Pacific Medical Centres Pty Ltd | 002 866 382 | Australia |
| PHC (No. 01) Pty Limited | 002 769 155 | Australia |
| PHC Diagnostic Imaging Holdings Pty Ltd | 080 527 699 | Australia |
| PHC Employee Share Acquisition Plan Pty Ltd | 085 060 046 | Australia |
| PHC Finance (Australia) Pty Ltd | 076 865 435 | Australia |
| PHC Healthcare Holdings Pty Ltd | 078 954 631 | Australia |
| PHC Medical Centre Holdings Pty Ltd | 088 128 787 | Australia |
| PHC Nominees Pty Ltd | 123 240 988 | Australia |
| PHC Pathology Holdings Asia Pty Ltd | 123 035 549 | Australia |
| PHC Pathology Holdings Pty Ltd | 088 128 778 | Australia |
| Phoenix Medical Publishing Pty Ltd | 122 121 260 | Australia |
| Primary (Camden) Pty Ltd | 603 192 445 | Australia |
| Primary (Richmond) Pty Ltd | 603 205 107 | Australia |
| Primary Health Care Institute Pty Ltd | 164 026 546 | Australia |
| Primary Health Care Limited | 064 530 516 | Australia |
| Primary Health Care Network Pty Ltd | 169 588 096 | Australia |
| Primary Health Insurance Pty Ltd | 169 492 040 | Australia |
| Primary Millers Point Pty Ltd | 602 716 834 | Australia |
| Primary Training Institute Pty Ltd | 150 738 686 | Australia |
| PSCP Holdings Pty Ltd | 119 887 651 | Australia |
| Queensland Diagnostic Imaging Pty Ltd | 070 000 654 | Australia |
| Queensland Medical Services Pty Ltd | 010 904 588 | Australia |
| Queensland Specialist Services Pty Ltd | 076 651 977 | Australia |
| Saftsal Pty Ltd | 092 452 287 | Australia |
| SDS Healthcare Solutions Inc. | CS201501588 | Philippines |
| Sidameneo (No. 456) Pty Ltd | 089 995 817 | Australia |
| Specialist Diagnostic Services Pathology (India) Private Limited | U72200KA2007FTC042522 | India |
| Specialist Diagnostic Services Pty Ltd | 007 190 043 | Australia |
| Specialist Haematology Oncology Services Pty Ltd | 169 843 163 | Australia |
| Specialist Veterinary Services Pty Ltd | 006 909 173 | Australia |
| Sumbrella Pty Ltd | 132 739 345 | Australia |
| Symbion Holdings (UK) Ltd | 4002585 | UK |
| Symbion International B.V. | 006810743 | Netherlands |
| The Ward Corporation Pty Ltd | 007 414 048 | Australia |
| Transport Health Pty Limited | 099 028 127 | Australia |
| Transport Security Insurance (Pte) Ltd | 00528/1989-R | Singapore |
| Wellness Holdings Pty Ltd | 091 862 207 | Australia |

Vision Eye Institute Limited (ACN 098 890 816)

Annexure B

This is Annexure B of 4 pages referred to in Form 605 Notice of ceasing to be a substantial shareholder.

| 0 | | | | |
|----|----------|----|----|------|
| Si | α | าว | tu | ır۵ |
| J | u | ıa | ιu | II C |

| print name | CHARLES TILLEY | capacity | COMPANY SECRETARY |
|------------|----------------|----------|-------------------|
| sign here | Um Tilly | date | 10/08/2015 |

A copy of the executed Share Sale Agreement dated 30 July 2015 follows.



SHARE SALE AGREEMENT

Date: 30 JULY 2015

Between:

Idameneo (No 123) Pty Limited

Jangho Group Co, Ltd

(ACN 002 968 185)

Level 31, 100 Miller Street North Sydney NSW 2060

AUSTRALIA

("Seller") ("Buyer")

STRICTLY PRIVATE & CONFIDENTIAL

We record our agreement as follows:

Recitals

- Vision Eye Institute Limited (ACN 098 890 816) is a company incorporated in Australia and has its registered office at Level 5, 390 St Kilda Road Melbourne VIC 3004 ("Company").
- The Company has issued 179,920,730 fully paid ordinary voting shares ("Shares").
- The Seller warrants that it is the registered holder and beneficial owner of approximately 41.6 million Shares in the capital of the Company.
- 4 The Seller is a wholly owned subsidiary of Primary Health Care Limited (ACN 064 530 516).

Sale and purchase of Sale Shares

- 5 Subject to the terms and conditions of this agreement:
 - (a) the Seller agrees to sell to the Buyer (or its nominee) free from encumbrances and security interests; and
 - (b) the Buyer (or its nominee) agrees to purchase from the Seller,

35,984,135 Shares ("Sale Shares") at AUD 0.94 per Sale Share for an aggregate amount of AUD 33,825,086.90 ("Purchase Price").

Completion

- On or prior to 5.00 pm (Sydney time) on Friday 7 August 2015 ("Completion Date"):
 - (a) the Seller will:
 - in respect of Sale Shares that are held on the Company's issuer-sponsored subregister, deliver to the Buyer a duly executed transfer in registrable form, in favour of Buyer (or its nominee), for the Sale Shares;
 - (ii) in respect of Sale Shares that are held on the Company's CHESS-sponsored subregister, procure performance of all that is required by the Settlement Operating Rules of the Australian Securities Exchange ("ASX") for the Sale Shares to be transferred to the Buyer (or its nominee); and

- (iii) in respect of all Sale Shares, deliver to the Buyer an original version or certified copy of the holding statements which disclose ownership of the Sale Shares, or any other evidence of shareholding that would be reasonable in the circumstances; and
- (b) the Buyer will, against the Seller's delivery of the Sale Shares, pay to the Seller an amount equal to the Purchase Price, in immediately available funds, to an account notified to the Buyer by the Seller not later than 2 business days in New South Wales, Australia prior to the Completion Date.

Simultaneous acts at Completion

- 7 In respect of completion under clause 6 ("Completion"):
 - (a) the obligations of the parties under this agreement are interdependent; and
 - (b) all actions required to be performed by a party at Completion are taken to have occurred simultaneously on the Completion Date.

Representations and warranties

Each party represents and warrants to the other that no regulatory or other third party approvals or consents of any kind are required for it to enter into this agreement or complete the transactions contemplated by it.

General

- The parties agree to pay their own legal and other costs and expenses in connection with the preparation, execution and completion of this agreement and other related documentation. The Buyer agrees to pay any stamp duty, if applicable.
- This agreement and, to the extent permitted by law, all related matters including noncontractual matters is governed by the laws of New South Wales, Australia. In relation to those matters each party irrevocably accepts the non exclusive jurisdiction of courts with jurisdiction there and waives any right to object to the venue on any ground.
- Each party agrees, at its own expense, on the request of a party, to do everything reasonably necessary to give effect to this agreement and the transactions contemplated by it, including, but not limited to, the execution of documents.
- This agreement may be executed in counterparts. All counterparts when taken together are to be taken to constitute one instrument.

[Signatures on following page]

Signing page

| As authorised representative for JANGHO GROUP CO, LTD in the presence of: Signature of witness | By executing this agreement the |
|---|--|
| Name of witness (block letters) | signatory warrants that the signatory is duly authorised to execute this agreement on behalf of JANGHO GROUP CO, LTD |
| PTY LIMITED in accordance with section 127(1) of the Corporations Act 2001 (Cth) by authority of its directors: | |
| Signature of director PETER GREGG | Signature of-director/company secretary* *delete whichever is not applicable STILLEY |
| MANAGING DIRECTOR | COMPANY SECRETARY Name of director/company secretary* (block letters) *delete whichever is not applicable |